Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. Additionally we are shipping CTLA4 Antibodies (451) and CTLA4 Kits (47) and many more products for this protein.
Showing 10 out of 85 products:
Mouse (Murine) CTLA4 Protein expressed in CHO Cells - ABIN2666795
Gerold, Zheng, Rainbow, Zernecke, Wicker, Kissler: The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. in Diabetes 2011
Show all 7 references for 2666795
Human CTLA4 Protein expressed in CHO Cells - ABIN2666793
Mittal, Chaturvedi, Rohlfsen, Gupta, Joshi, Hegde, Bociek, Joshi: Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. in PLoS ONE 2013
Show all 7 references for 2666793
Human CTLA4 Protein expressed in CHO Cells - ABIN2666967
Lindsten, Lee, Harris, Petryniak, Craighead, Reynolds, Lombard, Freeman, Nadler, Gray: Characterization of CTLA-4 structure and expression on human T cells. in Journal of immunology (Baltimore, Md. : 1950) 1993
Show all 3 references for 2666967
Human CTLA4 Protein expressed in HEK-293 Cells - ABIN2487344
Ross, Robinson, Amato, McMillan, Westcott, Wolf, Robinson: Therapeutic monoclonal antibodies in human breast milk: a case study. in Melanoma research 2014
Show all 2 references for 2487344
Human CTLA4 Protein expressed in Escherichia coli (E. coli) - ABIN1098772
Rudd, Taylor, Schneider: CD28 and CTLA-4 coreceptor expression and signal transduction. in Immunological reviews 2009
Show all 2 references for 1098772
Cynomolgus CTLA4 Protein expressed in HEK-293 Cells - ABIN2180929
Magistrelli, Jeannin, Herbault, Benoit De Coignac, Gauchat, Bonnefoy, Delneste: A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. in European journal of immunology 1999
CTLA-4 expressed by FOXP3 (show FOXP3 Proteins)(+) regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis.
results are consistent with a complex pathway in which CD28 (show CD28 Proteins) is the primary driver of Treg proliferation and CTLA-4 functions as the main brake but is also dependent on TCR signals and interactions with CD80 (show CD80 Proteins)/CD86 (show CD86 Proteins)
CTLA-4(+) microvesicles can competitively bind B7 costimulatory molecules on bystander dendritic cells, resulting in downregulation of B7 surface expression.
this study shows that miR (show MLXIP Proteins)-155 is modulated by a major dust mite allergen, Dermatophagoides farinae (Df1), and increases CD4 (show CD4 Proteins)+ T cell proliferation through the downregulation of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expression
CTLA-4 regulates atherosclerosis by suppressing proatherogenic immune responses.
Data suggest enhanced clinical benefit from combining CTLA-4 antigen blockade with poxvirus-based active immunotherapy.
up-regulated expression correlates with the tolerogenic effect of syngeneic hematopoietic stem cell transplantation
Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner
CTLA-4 has a regulatory T cell-intrinsic role in limiting peripheral regulatory T cell expansion and activation, and in their capacity to control conventional T cells.
The Ctla4 SNP (e2_77A/G) does not alter diabetes susceptibility, but does control mRNA alternative splicing.
AUthors observed a significant correlation between the proportion of Tregs and (in)CTLA-4+ Tregs with IL-17A (show IL17A Proteins) concentration in clBALF. Data confirmed significant differences in the proportion of regulatory elements between cancerous lung and healthy lung and PB and the usefulness of BALF analysis in evaluation of immune response regulation in local lung cancer environment.
CTLA-4 was expressed and functional on human breast cancer cells through influencing maturation and function of DCs in vitro, and CTLA-4 blockage not only recovered the antigen-presenting function of DCs and T-cells activation but also suppressed the biological activity of breast cancer cells themselves.
For anti-CTLA4 therapy, there were no data retrievable on clinical efficacy. Although data on clinical efficacy of checkpoint inhibitors in metastatic bladder cancer are currently limited, the efficacy of these drugs might depend mainly on the metastatic volume and immune system integrity. Patients with PD-L1 (show CD274 Proteins) positive tumors and non-visceral metastases seem to derive the highest benefit from therapy.
interpreting the functional significance of mutations in the CTLA-4 pathway identified by gene-sequencing approaches
In multivariable analysis, patients receiving cord blood units with GG-CTLA4 genotype had poorer neutrophil recovery, increased non-relapse mortality, and inferior disease-free survival.
CTLA-4 +49 A/G polymorphism is not associated with Henoch-Schonlein purpura (HSP).
Combined IL-21 (show IL17C Proteins)-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
High CTLA4 Circulating Levels are associated with Breast Cancer.
The CTLA4-CD28 (show CD28 Proteins) gene fusion is likely a major contributor to the pathogenesis of T-cell lymphomas and represents a potential target for anti-CTLA4 cancer immunotherapy.
Suggest a truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin as a novel approach for in vivo depletion of CD80 (show CD80 Proteins)-positive cells.
The surface expression of CTLA-4 was increased in subclinical stages of paratuberculosis infection while levels of ZAP-70 (show ZAP70 Proteins) were decreased in CD4 (show CD4 Proteins)+ T cells of both subclinical and clinical animals, indicating a change in T cell phenotype with disease state.
These results suggested that the expression level of CTLA-4 in CD4 (show CD4 Proteins)-positive T cells has a potentially immunosuppressive function in bovine leukemia infection.
Experimental infection with bovine viral diarrhea virus did not provide evidence ofTreg activation based on expression of FoxP3 (show FOXP3 Proteins) and CTLA4.
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
cytotoxic T-lymphocyte-associated protein 4 precursor
, CD152 protein
, cytotoxic T-lymphocyte protein 4
, cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM
, cytotoxic T-lymphocyte-associated protein 4
, costimulatory molecule B7 receptor
, cytotoxic T lymphocyte-associated antigen 4
, CD152 antigen
, cytotoxic T-lymphocyte-associated antigen 4
, CD152 isoform
, celiac disease 3
, cytotoxic T lymphocyte associated antigen 4 short spliced form
, cytotoxic T-lymphocyte antigen 4
, cytotoxic T-lymphocyte-associated serine esterase-4
, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
, soluble form
, transmembrane form
, cytotoxic T lymphocyte-associated protein 4
, costimulatory molecule B7 receptor CD152